Blinatumomab is a new monoclonal antibody that is directed against CD3 (on T
cells) and CD19 (on B cells). The idea is to bring the B cells in proximity to
T cells so the T cells can " prime " and immune response against the B cells.
This antibody is very early in clinical development. I am not aware of any
clinical trials at this time studying the antibody.
Rick Furman, MD
> Hello fellow CLL/SLL,
> Are any of you aware of the new monclonal antibody technology's blinatumomab?
> Any comments on this new dual antibody technology or the clinical trials
> Merle, Cochranton, PA,
> dx 11-13-01 sll IIIbe grade 1
> at 52yrs with hypercalcimia
> 6 x chop & 8 x rituxan cmplt'd 4-11-02 with Complete Response
> vincristine neuropathy 3-18-02
> false neg. PET 8-12-02 pos.node biopsy 9-5-02
> 75 mo.PFS, reoccurance 10-10-08
> watch & learn, onc appt: 9-15-10